Live Feeds
Press Releases
Insider Trading
FDA Approvals
Analyst Ratings
Insider Trading
SEC filings
Market insights
Analyst Ratings
Alerts
Subscriptions
Settings
RSS Feeds
Live Feeds
Press Releases
Insider Trading
FDA Approvals
Analyst Ratings
Insider Trading
SEC filings
Market insights
Analyst Ratings
Alerts
Subscriptions
Settings
RSS Feeds
Publish
Dashboard
Subscribe to $GRAL
GRAIL Inc.
Subscribe to $GRAL
$GRAL
Medical Specialities
Health Care
IPO Year:
Exchange: NASDAQ
Recent Analyst Ratings for GRAIL Inc.
Date
Price Target
Rating
Analyst
4/21/2025
$32.00
Buy
Canaccord Genuity
11/27/2024
$16.00
Equal-Weight
Morgan Stanley
11/15/2024
Peer Perform
Wolfe Research
10/17/2024
Neutral
Guggenheim
See more ratings
GRAIL Inc.
Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
See more
Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)
4 - GRAIL, Inc. (0001699031) (Issuer)
10/10/24 7:45:32 PM ET
$GRAL
Medical Specialities
Health Care
